Biologic agents as adjunctive therapy for prostate cancer: A rationale for use with androgen deprivation

Nature Clinical Practice Urology

Volumn 4, Issue 2, 2007, Pages 82-94

  Nelson, Eric C ^a   Cambio, Angelo J ^b   Yang, Joy C ^a   Lara Jr , Primo N ^a   Evans, Christopher P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANSAMYCIN DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ATRASENTAN; AZD 0530; BEVACIZUMAB; BORTEZOMIB; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GELDANAMYCIN; GENISTEIN; GROWTH FACTOR; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90; MATRIX METALLOPROTEINASE INHIBITOR; MBS 354825; MONOCLONAL ANTIBODY; OGX 011; PARATHYROID HORMONE RELATED PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN ANTAGONIST; SEROTONIN DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; APOPTOSIS; CANCER CELL; CANCER GROWTH; CASTRATION; CELL SUBPOPULATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG USE; ENZYME INHIBITION; HORMONE DETERMINATION; HUMAN; HYPERCALCEMIA; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANDROGENS; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 33846958453     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0700     Document Type: Review

References (100)

1. Jemal A et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106-130
2. Smaletz O et al. (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20: 3972-3982
3. Sharifi N and Farrar WL (2006) Androgen receptor as a therapeutic target for androgen independent prostate cancer. Am J Ther 13:166-170
4. Feldman BJ and Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
5. So A et al. (2005) Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23: 1-9
6. Wu RC et al. (2005) Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr Rev 26: 393-399
7. Culig Z et al. (2004) Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 92: 265-271
8. Gioeli D et al. (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284
9. Lorenzo GD et al. (2003) Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer 2: 50-57
10. Lara PN Jr et al. (2004) Trastuzumab plus docetaxel in HER-2/ neu-positive prostate carcinoma: Final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100: 2125-2131
11. Ziada A et al. (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 80: 332-337
12. van der Poel HG (2004) Smart drugs in prostate cancer. Eur Urol. 45: 1-17
13. Smith MR and Nelson JB (2005) Future therapies in hormone-refractory prostate cancer. Urology 65: 9-16; discussion 17
14. Canil CM et al. (2005) Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23: 455-460
15. Krueckl SL et al. (2004) Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64: 8620-8629
16. Miyake H et al. (2000) Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60: 3058-3064
17. Kiyama S et al. (2003) Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63: 3575-3584
18. Miyata Y et al. (2004) Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: Correlation with histopathologic effects and biochemical recurrence. Urology 63:1184-1190
19. Papandreou CN et al. (1998) Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4: 50-57
20. Lee LF et al. (2001) Neuropeptide-induced androgen independence in prostate cancer cells: Roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 21: 8385-8397
21. Amorino GP and Parsons SJ (2004) Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 14: 287-300
22. Song L et al. (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66: 5542-5548
23. Yang JC et al. (2005) Src kinase inhibition of neuropeptide-induced androgen-independent prostate cancer. Proc Amer Assoc Cancer Res 46: 3180
24. Nam S et al. (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65: 9185-9189
25. McDonnell TJ et al. (1992) Expression of the protooncogene bc1-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944
26. Colombel M et al. (1993) Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400
27. Shi Y et al. (2006) Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: An in vitro model that corroborates clinical observations. BJU Int 97: 170-178
28. Miyake H et al. (2001) Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. Int J Urol 8: 337-349
29. Tolcher AW et al. (2005) A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11: 3854-3861
30. Gleave M et al. (2005) Beyond simple castration: Targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol 56 (Suppl 1): 47-57
31. July LV et al. (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50: 179-188
32. Miyake H et al. (2005) Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol 12: 785-794
33. Chi KN et al. (2005) A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleoticle to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-1296
34. Baretton GB et al. (1999) Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80: 546-555
35. Wikstrom P et al. (1999) Early castration-induced upregulation of transforming growth factor beta1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate 38: 268-277
36. Chevalier S et al. (2002) Vascular endothelial growth factor and signaling in the prostate: More than angiogenesis. Mol Cell Endocrinol 189: 169-179
37. George DJ et al. (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7: 1932-1936
38. Lara PN Jr et al. (2004) Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 3: 165-173
39. Picus J et al. (2003) The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc Am Soc Clin Oncol 22: 393
40. Schlaepfer DD and Hunter T (1998) Integrin signalling and tyrosine phosphorylation: Just the FAKs? Trends Cell Biol 8: 151-157
41. Danen EH and Yamada KM (2001) Fibronectin, integrins, and growth control. J Cell Physiol 189: 1-13
42. Stewart DA et al. (2004) Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod Biol Endocrinol 2: 2
43. Stubbs AP et al. (1999) Differentially expressed genes in hormone refractory prostate cancer: Association with chromosomal regions involved with genetic aberrations. Am J Pathol 154: 1335-1343
44. Legrier ME et al. (2004) Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft. Br J Cancer 90: 720-727
45. North SA et al. (2006) A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 176: 91-95
46. Kousidou O et al. (2006) Effects of the natural isoflavonoid genistein on growth, signaling pathways and gene expression of matrix macromolecules by breast cancer cells. Mini Rev Med Chem 6: 331-337
47. Papandreou CN and Logothetis CJ (2004) Bortezomib as a potential treatment for prostate cancer. Cancer Res 64: 5036-5043
48. Orlowski RZ and Baldwin AS Jr (2002) NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389
49. Price N and Dreicer R (2004) Phase I/II trial of bortezomib plus docetaxell in patients with advanced androgen-independent prostate cancer. Clin Prostate Cancer 3: 141-143
50. Papandreou CN et al. (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22: 2108-2121
51. Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
52. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512
53. Chung LW et al. (2005) Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. J Urol 173: 10-20
54. Gregory CW et al. (1998) Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58: 5718-5724
55. Hong H et al. (2004) Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 101: 83-89
56. Debes JD et al. (2002) p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62: 5632-5636
57. Halkidou K et al. (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22: 2466-2477
58. Culig Z et al. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478
59. Dorkin TJ et al. (1999) aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol 189: 564-569
60. Sirotnak FM et al. (2004) Microarray analysis of prostate cancer progression to reduced androgen dependence: Studies in unique models contrasts early and late molecular events. Mol Carcinog 41: 150-163
61. Bubendorf L et al. (1999) Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91: 1758-1764
62. Stewart RJ et al. (2001) Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 165: 688-693
63. Aslan G et al. (2005) Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract 201: 593-598
64. Zellweger T et al. (2005) Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113: 619-628
65. Naimi B et al. (2002) Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 52: 245-252
66. Dizeyi N et al. (2005) Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol 47: 895-900
67. Jongsma J et al. (2000) Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 60: 741-748
68. Salido M et al. (2002) Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines. Cancer 94: 368-377
69. Takahashi W et al. (2003) Regulatory effect of castration on endothelins, their receptors and endothelin-converting enzyme in rat seminal vesicle. BJU Int 92: 803-809
70. Yashi M et al. (2003) Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate 56: 305-312
71. Levine L et al. (2003) Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 63: 3495-3502
72. Yuan TC et al. (2006) Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 13: 151-167
73. Vashchenko N and Abrahamsson PA (2005) Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 47: 147-155
74. Gutierrez-Canas I et al. (2005) Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and P13K. Prostate 63:44-55
75. Sugihara A et al. (1998) Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: An immunohistochemical study. Oncol Rep 5: 1389-1394
76. Wise GJ et al. (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164: 722-725
77. Lee LF et al. (2004) Interleukin-8 confers androgen-independent growth and migration of LNCaP: Differential effects of tyrosine kinases; Src and FAK. Oncogene 23: 2197-2205
78. Huerta-Yepez S et al. (2006) Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol 120: 297-309
79. Watson RW and Fitzpatrick JM (2005) Targeting apoptosis in prostate cancer: Focus on caspases and inhibitors of apoptosis proteins. BJU Int 96 (Suppl 2): 30-34
80. Koivisto PA and Rantala I (1999) Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 187: 237-241
81. Pflug BR et al. (1999) Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 40: 269-273
82. Persad S and Dedhar S (2003) The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev 22: 375-384
83. Miyamoto H et al. (2005) Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Mol Carcinog 44: 1-10
84. Kiviniemi J et al. (2004) Altered expression of syndecan- 1 in prostate cancer. Apmis 112: 89-97
85. Lokeshwar BL (1999) MMP inhibition in prostate cancer. Ann N Y Acad Sci 878: 271-289
86. Bratland A et al. (2003) The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells. Clin Exp Metastasis 20: 541-547
87. Nishiyama T et al. (2004) The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10: 7121-7126
88. Lei Q et al. (2006) NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9: 367-378
89. Majumder PK and Sellers WR (2005) Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474
90. Edwards J et al. (2004) The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. J Pathol 204: 153-158
91. Aprikian AG et al. (1996) Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 16: 297-306
92. Sumitomo M et al. (2001) Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 61: 3294-3298
93. Devi GR et al. (2005) In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res 11: 3930-3938
94. Smith MR et al. (2006) Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24: 2723-2728
95. Pruthi RS et al. (2003) Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: A review. J Urol 189: 2352-2359
96. Ling MT et al. (2004) Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Carcinogenesis 25: 517-525
97. Ettinger SL et al. (2004) Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64: 2212-2221
98. Sasaki T et al. (2005) Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 48: 224-229; discussion 229-230
99. Imasato Y et al. (2000) PSP94 expression after androgen deprivation therapy: A comparative study with prostate specific antigen in benign prostate and prostate cancer. J Urol 164: 1819-1824
100. Rittmaster RS et al. (1999) The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer. J Urol 162: 2165-2169